To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: Pilot study using dynamic contrast-enhanced Doppler ultrasound

Lamuraglia, Michele; Escudier, Bernard; Chami, L.; Schwartz, Brian; Leclère, J.; Roche, Alain; Lassau, Nathalie

doi:10.1016/j.ejca.2006.04.023

Cited by 155 publications

(100 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Consistent with the preclinical data in RCC xenograft models, correlative science studies in RCC patients using dynamic contrast-enhanced Doppler ultrasound with perfusion software showed that good responders had a significant decrease (60%) in contrast uptake after 3 weeks of treatment with sorafenib 400 mg bid. In this study, good response by dynamic contrast-enhanced Doppler ultrasound was shown to correlate with a statistically significant difference in progression-free survival in this cohort of RCC patients compared with poor response (59). Similar findings in a recent dynamic contrast-enhanced magnetic resonance imaging study in RCC patients enrolled in an open-label pilot study (60) showed a significant decrease in K trans or vascular permeability after 12 weeks of sorafenib 400 mg bid.…”

Section: Renal Cell Carcinomasupporting

confidence: 71%

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

Wilhelm

Adnane

Newell

et al. 2008

Molecular Cancer Therapeutics

1,271

861

View full text Add to dashboard Cite

Although patients with advanced refractory solid tumors have poor prognosis, the clinical development of targeted protein kinase inhibitors offers hope for the future treatment of many cancers. In vivo and in vitro studies have shown that the oral multikinase inhibitor, sorafenib, inhibits tumor growth and disrupts tumor microvasculature through antiproliferative, antiangiogenic, and/or proapoptotic effects. Sorafenib has shown antitumor activity in phase II/III trials involving patients with advanced renal cell carcinoma and hepatocellular carcinoma. The multiple molecular targets of sorafenib (the serine/threonine kinase Raf and receptor tyrosine kinases) may explain its broad preclinical and clinical activity. This review highlights the antitumor activity of sorafenib across a variety of tumor types, including renal cell, hepatocellular, breast, and colorectal carcinomas in the preclinical setting. In particular, preclinical evidence that supports the different mechanisms of action of sorafenib is discussed. [Mol Cancer Ther 2008;7(10):3129 -40]

show abstract

Section: Renal Cell Carcinomasupporting

confidence: 71%

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

Wilhelm

Adnane

Newell

et al. 2008

Molecular Cancer Therapeutics

1,271

861

View full text Add to dashboard Cite

show abstract

“…Patients and methods: CT scans from 32 patients with metastatic RCC treated with either sunitinib (18) or cediranib (14) were assessed. Twelve patients were excluded from the analysis as ten had non-contrast enhanced scans due to renal impairment and two stopped treatment due to toxicity.…”

Section: Introductionmentioning

confidence: 99%

CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies

Nathan¹,

Vinayan²,

Stott³

et al. 2010

Cancer Biology & Therapy

104

View full text Add to dashboard Cite

Original article can be found at: http://www.landesbioscience.com/journals/cbt/ Copyright Landes Bioscience [Full text of this article is not available in the UHRA]Background: Response assessment is critical in evaluating effectiveness of anticancer treatment. Tyrosine kinase inhibitors (TKIs) in renal cell carcinoma (RCC) are associated with significant clinical benefit but may not result in significant tumour size reduction. Thus standard size-based response assessment with RECIST is insensitive, resulting in low response rates which do not reflect disease control measured by time to progression. We compared the use of combined size and density response criteria with standard size based criteria in metastatic RCC patients treated with TKI's. Patients and methods: CT scans from 32 patients with metastatic RCC treated with either sunitinib (18) or cediranib (14) were assessed. 12 patients were excluded from the analysis as 10 had non-contrast enhanced scans due to renal impairment and 2 stopped treatment due to toxicity. Scans from 20 evaluable patients at baseline and 12 weeks on treatment were assessed using RECIST, Choi, and modified criteria in which both a 10% decrease in size and 15% decrease in density were required to define a partial response (PR). Response assessment performed using each of the three methods was compared with time to disease progression (TTP) defined by RECIST using Kaplan-Meier statistics and Log-rank test with significance at 5%. Results: Partial response (PR) and stable disease (SD) defined by modified criteria successfully identified patients with a long TTP (448 days) or short TTP (89 days) respectively (p=0.002). Neither RECIST nor standard Choi criteria successfully discriminated between patients having a short or long clinical benefit. Conclusion: A combined reduction in both size and arterial phase density of RCC metastases treated with TKIs correlates with TTP. RECIST and standard Choi criteria appear inferior

show abstract

“…In general, the xenograft models are very informative and allow for several types of measurements to be performed simultaneously including caliper measurements, IVIS imaging, ultrasonography with and without the contrast agents, PET and MRI imaging, measurements of serum or urine biomarkers and finally deployment of many histological and histochemical methods. Recently, several groups have demonstrated that quantification of intra-tumoral flow of an ultrasound contrast agent with gray-scale imaging can be used for monitoring tumor vascular response to anti-angiogenic therapy in animal models, a technique that can also be used in the clinic [13][14][15][16]. In those studies data obtained with ultrasonography paralleled tumor volume data obtained by caliper measurement and showed good correlation with tumor histology, allowing assessment of necrotic and perfused tumor areas in vivo.…”

Section: Tumor Vasculature In Xenograft Hcc Modelmentioning

confidence: 68%

Use of Ultrasound to Assess Drug Efficacy in Orthotopic Rat Models of HCC

Bagi¹,

Swanson²,

Tuthill³

2011

Ultrasound Imaging - Medical Applications

View full text Add to dashboard Cite

To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: Pilot study using dynamic contrast-enhanced Doppler ultrasound

Cited by 155 publications

References 26 publications

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies

Use of Ultrasound to Assess Drug Efficacy in Orthotopic Rat Models of HCC

Contact Info

Product

Resources

About